Mercury Laboratories Limited
Bombay Stock ExchangeTotal Valuation
Mercury Laboratories Limited carries a market capitalization of 966.00M, placing it among publicly traded companies globally. Its enterprise value stands at 973.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 966.00M |
| Enterprise Value | 973.77M |
Valuation Ratios
Mercury Laboratories Limited trades at a trailing price-to-earnings ratio of 20.64.
| PE Ratio | 20.64 |
| PS Ratio | 1.28 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Mercury Laboratories Limited trades at an EV/EBITDA multiple of 10.71 and an EV/FCF ratio of 611.20. The EV/Sales ratio of 1.28 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 10.71 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.28 |
| EV / EBITDA | 10.71 |
| EV / EBIT | 10.71 |
| EV / FCF | 611.20 |
Financial Position
Mercury Laboratories Limited maintains a current ratio of 6.10, meaning it holds 6.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.94, indicating elevated leverage, while an interest coverage ratio of 42.43 demonstrates strong ability to service its debt obligations.
| Current Ratio | 6.10 |
| Quick Ratio | 0.36 |
| Debt / Equity | 20.94 |
| Debt / EBITDA | N/A |
| Interest Coverage | 42.43 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 99.78 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Mercury Laboratories Limited has paid 16.28M in income taxes, reflecting an effective tax rate of 25.66.
| Income Tax | 16.28M |
| Effective Tax Rate | 25.66 |
Stock Price Statistics
Mercury Laboratories Limited's stock has declined approximately -1.99063% over the past 52 weeks. The 50-day moving average sits at 770.67, while the 200-day moving average is 816.96.
| Beta (5Y) | N/A |
| 52-Week Price Change | -1.99063% |
| 50-Day Moving Average | 770.67 |
| 200-Day Moving Average | 816.96 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Mercury Laboratories Limited generated 761.53M in revenue and converted that into 47.19M in net income, yielding earnings per share of 39.31. EBITDA reached 90.93M, while operating income came in at 90.93M.
| Revenue | 761.53M |
| Gross Profit | 464.24M |
| Operating Income | 90.93M |
| Pretax Income | 63.47M |
| Net Income | 47.19M |
| EBITDA | 90.93M |
| EBIT | 90.93M |
| Earnings Per Share (EPS) | 39.31 |
Margins
Mercury Laboratories Limited operates with a gross margin of 60.96, reflecting its pricing power and cost economics. The operating margin of 11.94 and net profit margin of 6.20 provide insight into operational efficiency.
| Gross Margin | 60.96 |
| Operating Margin | 11.94 |
| Pretax Margin | 8.33 |
| Profit Margin | 6.20 |
| EBITDA Margin | 11.94 |
Scores
Mercury Laboratories Limited posts an Altman Z-Score of 7.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.07 |